{"id":"https://openalex.org/W2029005246","doi":"https://doi.org/10.2165/00003088-200645080-00003","title":"Lack of Pharmacokinetic Interaction for ISIS 113715, a 2???-0-Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or Rosiglitazone","display_name":"Lack of Pharmacokinetic Interaction for ISIS 113715, a 2???-0-Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or Rosiglitazone","publication_year":2006,"publication_date":"2006-01-01","ids":{"openalex":"https://openalex.org/W2029005246","doi":"https://doi.org/10.2165/00003088-200645080-00003","mag":"2029005246","pmid":"https://pubmed.ncbi.nlm.nih.gov/16884318"},"language":"en","primary_location":{"id":"doi:10.2165/00003088-200645080-00003","doi":"https://doi.org/10.2165/00003088-200645080-00003","is_oa":false,"landing_page_url":"https://doi.org/10.2165/00003088-200645080-00003","pdf_url":null,"source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056554811","display_name":"Richard S. Geary","orcid":"https://orcid.org/0000-0002-6308-3179","observed_orcids":["https://orcid.org/0000-0002-6308-3179"]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Richard S Geary","raw_affiliation_strings":["ISIS Pharmaceuticals, Inc., Carlsbad, California 92008, USA. rgeary@isisph.com","Isis Pharmaceuticals, Inc. Carlsbad, California 92008, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ISIS Pharmaceuticals, Inc., Carlsbad, California 92008, USA. rgeary@isisph.com","institution_ids":[]},{"raw_affiliation_string":"Isis Pharmaceuticals, Inc. Carlsbad, California 92008, USA","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061873050","display_name":"JoAnn D. Bradley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"JoAnn D Bradley","raw_affiliation_strings":["ISIS Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, California, 92008, USA","Isis Pharmaceuticals, Inc, Carlsbad, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ISIS Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, California, 92008, USA","institution_ids":[]},{"raw_affiliation_string":"Isis Pharmaceuticals, Inc, Carlsbad, USA","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086886197","display_name":"Tanya A. Watanabe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tanya Watanabe","raw_affiliation_strings":["ISIS Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, California, 92008, USA","Isis Pharmaceuticals, Inc, Carlsbad, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ISIS Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, California, 92008, USA","institution_ids":[]},{"raw_affiliation_string":"Isis Pharmaceuticals, Inc, Carlsbad, USA","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049527089","display_name":"Younggil Kwon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Younggil Kwon","raw_affiliation_strings":["ISIS Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, California, 92008, USA","Isis Pharmaceuticals, Inc, Carlsbad, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ISIS Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, California, 92008, USA","institution_ids":[]},{"raw_affiliation_string":"Isis Pharmaceuticals, Inc, Carlsbad, USA","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111818669","display_name":"Mark K. Wedel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800035258","display_name":"Ionis Pharmaceuticals (United States)","ror":"https://ror.org/00t8bew53","country_code":"US","type":"company","lineage":["https://openalex.org/I2800035258"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Wedel","raw_affiliation_strings":["ISIS Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, California, 92008, USA","Isis Pharmaceuticals, Inc, Carlsbad, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ISIS Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, California, 92008, USA","institution_ids":[]},{"raw_affiliation_string":"Isis Pharmaceuticals, Inc, Carlsbad, USA","institution_ids":["https://openalex.org/I2800035258"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055811263","display_name":"Jan Jaap van Lier","orcid":"https://orcid.org/0000-0001-9676-5136","observed_orcids":["https://orcid.org/0000-0001-9676-5136"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jan J van Lier","raw_affiliation_strings":["Pharma Bio-Research Group B.V., Zuidlaren, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Bio-Research Group B.V., Zuidlaren, The Netherlands","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111777135","display_name":"Andr A vanVliet","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andr?? A vanVliet","raw_affiliation_strings":["Pharma Bio-Research Group B.V., Zuidlaren, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Bio-Research Group B.V., Zuidlaren, The Netherlands","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5056554811"],"corresponding_institution_ids":["https://openalex.org/I2800035258"],"apc_list":{"value":4990,"currency":"USD","value_usd":4990},"apc_paid":null,"fwci":0.8059,"has_fulltext":false,"cited_by_count":50,"citation_normalized_percentile":{"value":0.68356589,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"45","issue":"8","first_page":"789","last_page":"801"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7705000042915344,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7705000042915344,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.02590000070631504,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.01679999940097332,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antisense-oligonucleotides","display_name":"antisense oligonucleotides","score":0.8140000104904175},{"id":"https://openalex.org/keywords/ptp1b","display_name":"PTP1B","score":0.9369999766349792},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.7369999885559082},{"id":"https://openalex.org/keywords/glipizide","display_name":"glipizide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/rosiglitazone","display_name":"rosiglitazone","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetic-interactions","display_name":"pharmacokinetic interactions","score":0.8500000238418579},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8510000109672546},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8199999928474426},{"id":"https://openalex.org/keywords/plasma-protein-binding","display_name":"plasma protein binding","score":0.7699999809265137},{"id":"https://openalex.org/keywords/oral-antidiabetic-drugs","display_name":"oral antidiabetic drugs","score":0.5889999866485596}],"concepts":[{"id":"https://openalex.org/C2779555806","wikidata":"https://www.wikidata.org/wiki/Q3108899","display_name":"Glipizide","level":3,"score":0.9332651495933533},{"id":"https://openalex.org/C2780152017","wikidata":"https://www.wikidata.org/wiki/Q424771","display_name":"Rosiglitazone","level":3,"score":0.8858262896537781},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6899712085723877},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6204572319984436},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.6197041273117065},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.47389402985572815},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.45272544026374817},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.3837820291519165},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.33677566051483154}],"mesh":[{"descriptor_ui":"D000077154","descriptor_name":"Rosiglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001798","descriptor_name":"Blood Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005913","descriptor_name":"Glipizide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005913","descriptor_name":"Glipizide","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009843","descriptor_name":"Oligoribonucleotides","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D009843","descriptor_name":"Oligoribonucleotides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D017027","descriptor_name":"Protein Tyrosine Phosphatases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D017027","descriptor_name":"Protein Tyrosine Phosphatases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D054562","descriptor_name":"Protein Tyrosine Phosphatase, Non-Receptor Type 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2165/00003088-200645080-00003","doi":"https://doi.org/10.2165/00003088-200645080-00003","is_oa":false,"landing_page_url":"https://doi.org/10.2165/00003088-200645080-00003","pdf_url":null,"source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},{"id":"pmid:16884318","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16884318","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacokinetics","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1496645167","https://openalex.org/W1851111672","https://openalex.org/W1918439017","https://openalex.org/W1961577685","https://openalex.org/W1985777098","https://openalex.org/W1989842082","https://openalex.org/W1996678268","https://openalex.org/W2016247822","https://openalex.org/W2024858641","https://openalex.org/W2032810973","https://openalex.org/W2047511891","https://openalex.org/W2053544216","https://openalex.org/W2054575721","https://openalex.org/W2066394912","https://openalex.org/W2083420496","https://openalex.org/W2086002435","https://openalex.org/W2104954969","https://openalex.org/W2116500202","https://openalex.org/W2143228863","https://openalex.org/W2144634347","https://openalex.org/W2147730379","https://openalex.org/W2161599977","https://openalex.org/W2169218609","https://openalex.org/W2255911290","https://openalex.org/W2399825601","https://openalex.org/W2434243098"],"related_works":["https://openalex.org/W1985816784","https://openalex.org/W2953197675","https://openalex.org/W2092075902","https://openalex.org/W1976883244","https://openalex.org/W2892099068","https://openalex.org/W2016004150","https://openalex.org/W2031763777","https://openalex.org/W2790715244","https://openalex.org/W130143555","https://openalex.org/W2080783302"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":2},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}